Limits...
A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee.

Vishal AA, Mishra A, Raychaudhuri SP - Int J Med Sci (2011)

Bottom Line: A series of biochemical tests in serum, urine and hematological parameters established the safety of Aflapin.Aflapin provided significant improvements in pain score and functional ability in as early as 5 days of treatment.In conclusion, our observations suggest that Aflapin is a safe, fast acting and effective alternative intervention in the management of OA.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Alluri Sitarama Raju Academy of Medical Sciences, National Highway 5, Eluru, 534 002, India.

ABSTRACT
Aflapin(®) is a novel synergistic composition derived from Boswellia serrata gum resin (Indian Patent Application No. 2229/CHE/2008). Aflapin is more efficacious as an anti-inflammatory agent compared to the existing Boswellia products, 5-Loxin(®) and traditional 65% Boswellia extract. A 30-day, double-blind, randomized, placebo-controlled study was conducted to validate the efficacy of Aflapin(®) in the management of clinical symptoms of osteoarthritis (OA) of the knee (Clinical trial registration number: ISRCTN69643551). Sixty eligible OA subjects selected through screening were included in the study. The subjects received either 100 mg (n=30) of Aflapin(®) or placebo (n=30) daily for 30 days. Each subject was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 5, 15 and 30. A series of biochemical tests in serum, urine and hematological parameters established the safety of Aflapin. The observations suggest that Aflapin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA subjects. Aflapin provided significant improvements in pain score and functional ability in as early as 5 days of treatment. In conclusion, our observations suggest that Aflapin is a safe, fast acting and effective alternative intervention in the management of OA.

Show MeSH

Related in: MedlinePlus

Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, serum biochemistry, hematology, urine biochemistry and pro-inflammatory biomarkers were done at baseline (day 0) and on days 5, 15 and 30 during follow up.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3198257&req=5

Figure 1: Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, serum biochemistry, hematology, urine biochemistry and pro-inflammatory biomarkers were done at baseline (day 0) and on days 5, 15 and 30 during follow up.


A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee.

Vishal AA, Mishra A, Raychaudhuri SP - Int J Med Sci (2011)

Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, serum biochemistry, hematology, urine biochemistry and pro-inflammatory biomarkers were done at baseline (day 0) and on days 5, 15 and 30 during follow up.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3198257&req=5

Figure 1: Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, serum biochemistry, hematology, urine biochemistry and pro-inflammatory biomarkers were done at baseline (day 0) and on days 5, 15 and 30 during follow up.
Bottom Line: A series of biochemical tests in serum, urine and hematological parameters established the safety of Aflapin.Aflapin provided significant improvements in pain score and functional ability in as early as 5 days of treatment.In conclusion, our observations suggest that Aflapin is a safe, fast acting and effective alternative intervention in the management of OA.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Alluri Sitarama Raju Academy of Medical Sciences, National Highway 5, Eluru, 534 002, India.

ABSTRACT
Aflapin(®) is a novel synergistic composition derived from Boswellia serrata gum resin (Indian Patent Application No. 2229/CHE/2008). Aflapin is more efficacious as an anti-inflammatory agent compared to the existing Boswellia products, 5-Loxin(®) and traditional 65% Boswellia extract. A 30-day, double-blind, randomized, placebo-controlled study was conducted to validate the efficacy of Aflapin(®) in the management of clinical symptoms of osteoarthritis (OA) of the knee (Clinical trial registration number: ISRCTN69643551). Sixty eligible OA subjects selected through screening were included in the study. The subjects received either 100 mg (n=30) of Aflapin(®) or placebo (n=30) daily for 30 days. Each subject was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 5, 15 and 30. A series of biochemical tests in serum, urine and hematological parameters established the safety of Aflapin. The observations suggest that Aflapin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA subjects. Aflapin provided significant improvements in pain score and functional ability in as early as 5 days of treatment. In conclusion, our observations suggest that Aflapin is a safe, fast acting and effective alternative intervention in the management of OA.

Show MeSH
Related in: MedlinePlus